Skip to main content

Table 1 Patient characteristics

From: Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient

Patient characteristics all <65 years ≥ 65 years
Number of Patients 88 73 15
Median age (range), years 56 (32–78)   
  n (%)   
Gender
 Female 31 (35.2) 29 (39.7) 2 (13.3)
 Male 57 (64.8) 44 (60.3) 13 (86.7)
ECOG PS
 0 49 (55.7) 43 (58.9) 6 (40.0)
 1 36 (40.9) 27 (37.0) 9 (60.0)
 2 3 (3.4) 3 (4.1) 0
Metastatic disease 79 (89.8) 64 (87.7) 15 (100.0)
Locally advanced tumor 9 (10.2) 9 (12.3) 0
Primary palliative treatment 66 (75.0) 55 (75.3) 11 (73.3)
Previous resection 22 (25.0) 18 (24.7) 4 (26.7)
 Prior (neo-) adjuvant CTX 13 (14.8) 11 (15.1) 2 (13.3)
Site of Tumor
 Pancreatic head 50 (56.8) 42 (57.5) 8 (53.3)
 Pancreatic corpus 22 (25.0) 20 (27.4) 2 (13.3)
 Pancreatic tail 16 (18.2) 11 (15.1) 5 (33.3)